Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Svrcek

Showing results (201-210 of 299) with videos related to

Pageof 30
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 24, 2019
Erratum to 'Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST)' [Eur J Cancer 107 (January 2019) 46-52]S Watson, C de la Fouchardière, S Kim, et al.
Journal of the National Cancer Institute|April 16, 2020
Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal CancerKaysia Ludford, Romain Cohen, Magali Svrcek, et al.
Cancer Treatment Reviews|December 26, 2021
A comprehensive overview of tumour deposits in colorectal cancer: Towards a next TNM classificationJean-François Delattre, Ayse Selcen Oguz Erdogan, Romain Cohen, et al.
International Journal of Radiation Oncology, Biology, Physics|August 13, 2019
Mismatch Repair System Deficiency Is Associated With Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal CancerNicolas Meillan, Dewi Vernerey, Jérémie H Lefèvre, et al.
Cancer Treatment Reviews|February 11, 2025
How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task forceChristelle de la Fouchardière, Antonella Cammarota, Magali Svrcek, et al.
Nature Communications|August 2, 2017
Charge carrier localised in zero-dimensional (CH<sub>3</sub>NH<sub>3</sub>)<sub>3</sub>Bi<sub>2</sub>I<sub>9</sub> clustersChengsheng Ni, Gordon Hedley, Julia Payne, et al.
Neuroendocrinology|September 4, 2015
Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine TumorsJerome Cros, Emilie Moati, Jerome Raffenne, et al.
Journal of the National Cancer Institute|October 7, 2010
Azathioprine-induced carcinogenesis in mice according to Msh2 genotypeAlexandra Chalastanis, Virginie Penard-Lacronique, Magali Svrcek, et al.
European Journal of Cancer (Oxford, England : 1990)|May 7, 2014
ERBB2 gene as a potential therapeutic target in small bowel adenocarcinomaAnais Laforest, Thomas Aparicio, Aziz Zaanan, et al.
The Oncologist|April 6, 2023
BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint InhibitorsRaphael Colle, Sara Lonardi, Marine Cachanado, et al.
Pageof 30

Showing results (201-210 of 299) with videos related to

Sort By:
Pageof 30
European Journal of Cancer (Oxford, England : 1990)|July 24, 2019
Erratum to 'Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST)' [Eur J Cancer 107 (January 2019) 46-52]S Watson, C de la Fouchardière, S Kim, et al.
Journal of the National Cancer Institute|April 16, 2020
Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal CancerKaysia Ludford, Romain Cohen, Magali Svrcek, et al.
Cancer Treatment Reviews|December 26, 2021
A comprehensive overview of tumour deposits in colorectal cancer: Towards a next TNM classificationJean-François Delattre, Ayse Selcen Oguz Erdogan, Romain Cohen, et al.
International Journal of Radiation Oncology, Biology, Physics|August 13, 2019
Mismatch Repair System Deficiency Is Associated With Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal CancerNicolas Meillan, Dewi Vernerey, Jérémie H Lefèvre, et al.
Cancer Treatment Reviews|February 11, 2025
How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task forceChristelle de la Fouchardière, Antonella Cammarota, Magali Svrcek, et al.
Nature Communications|August 2, 2017
Charge carrier localised in zero-dimensional (CH<sub>3</sub>NH<sub>3</sub>)<sub>3</sub>Bi<sub>2</sub>I<sub>9</sub> clustersChengsheng Ni, Gordon Hedley, Julia Payne, et al.
Neuroendocrinology|September 4, 2015
Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine TumorsJerome Cros, Emilie Moati, Jerome Raffenne, et al.
Journal of the National Cancer Institute|October 7, 2010
Azathioprine-induced carcinogenesis in mice according to Msh2 genotypeAlexandra Chalastanis, Virginie Penard-Lacronique, Magali Svrcek, et al.
European Journal of Cancer (Oxford, England : 1990)|May 7, 2014
ERBB2 gene as a potential therapeutic target in small bowel adenocarcinomaAnais Laforest, Thomas Aparicio, Aziz Zaanan, et al.
The Oncologist|April 6, 2023
BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint InhibitorsRaphael Colle, Sara Lonardi, Marine Cachanado, et al.
Pageof 30